Cardior Pharmaceuticals

Cardior Pharmaceuticals’ founder and CSO/CMO, the Head of Institute for Molecular and Translational Therapeutic Strategies (#IMTTS) of Hannover Medical School (#MHH) Professor Thomas Thum will take part in the DIA/FDA Oligonucleotide-Based Therapeutics Conference in Washington, DC this week and speak on Cardiac Delivery of Nucleotides on Monday 28 October at 11:00 ET. #Oligo24  

Cardior Pharmaceuticals’ CEO and Co-Founder Dr. Claudia Ulbrich is in Oslo this week to take part in Hadean Annual Event 2024 organized by #Hadeanventures held in the world famous #Munchmuseeum on October 23-24. In her company presentation Claudia will speak on the latest developments at Cardior as well as share her own experiences during this exciting journey from the inception of the company to its acquisition by Novo Nordisk, one of the most notable #lifescience deals in 2024. 

We want to congratulate the 2024 Nobel Prize winners for their remarkable discovery of microRNAs as key regulatory elements in the genome. This milestone has reshaped our understanding of gene regulation and its role in health and disease.   At Cardior, which was acquired by Novo Nordisk earlier in 2024, we are proud to be leading the world’s largest study on microRNA therapeutics in cardiovascular patients. The Nobel Prize-winning discovery of microRNAs forms the foundation of our pioneering work, as we leverage the knowledge to develop therapies that transform cardiovascular care and bring hope to patients in an area with significant unmet needs.   #Cardior #NovoNordisk #miRNA #DrivingChange #NobelPrize2024 #InnovativeMedicine #ScientificBreakthroughs

Join Dr. Sandor Batkai, M.D., Ph.D. , Cardior Pharmaceuticals’ Co-founder & Head of Medical Research and Intelligence, at the 3rd Annual Heart Failure Drug Discovery & Development Summit in Boston, MA.  The forum focuses entirely on preclinical research in #heartfailure drug development. On Thursday, August 1 Sandor is holding the presentation “Delving into Non-Coding RNA Pathways in Addressing Cardiac Diseases”. Check the agenda for details and stop by: https://lnkd.in/dMxPwGmR

We congratulate Vicente Godoy on the promotion to Vice President Quality Management & Compliance. Vicente has been with Cardior Pharmaceuticals as Head of Quality Management since March 2022 playing a decisive role in implementing and maintaining company’s quality management system. We wish him every success in this new position and welcome him to Cardior Leadership Team: https://lnkd.in/etQUFsZk

We are happy to announce that Prof. Dr. Dr. Thomas Thum, Cardior Pharmaceuticals’ CSO/CMO, and Dr. Claudia Ulbrich, Cardior’s CEO, are among the finalists of Andreas & Thomas Strüngmann Award, the first of its kind in the DACH region aimed at recognizing impressive entrepreneurial talents and achievements in the life sciences arena. We are very proud of Claudia & Thomas and wish them best of luck in the finals😊 More information in the official press release: https://lnkd.in/dBvvTNKJ

Cardior Pharmaceuticals’ CEO Dr. Claudia Ulbrich is participating in Biotech CEO Summit Europe in Barcelona on May 27-29 2024. On Monday May 27 Claudia is invited to speak at Fireside Chat moderated by Pankaj Oza of Blue Matter. Claudia will take time to share Cardior’s journey leading to the acquisition of Cardior by Novo Nordisk A/S completed on May 2, 2024 as well as reflect on her own experiences in the industry so far. The Summit brings together biotech industry leaders and offers an excellent opportunity for in-depth and open discussion. Learn more in the programme: https://lnkd.in/ewmqig8d

Cardior Pharmaceuticals’ founder and CSO/CMO, the Head of Institute for Molecular and Translational Therapeutic Strategies (#IMTTS) of Hannover Medical School (#MHH) Professor Thomas Thum is taking part at the World Congress on Acute Heart Failure held in Lisbon on May 11-14, 2024. Tomorrow at 13:45 (UTC+1) Thomas will be presenting the exciting journey starting from research on #microRNAs at the bench to clinical testing in heart failure patients. He will also be speaking on the mechanism of action of #CDR132L and its potential to tackle the root causes of acute and chronic #heartfailure. The presentation is part of the Symposium “Next Generation heart failure therapies”. Learn more in the programme: https://lnkd.in/dHepDsAu

Watch our CEO, Dr. Claudia Ulbrich in the Flot.bio podcast where she discusses the recent €1B acquisition of Cardior by Novo Nordisk. The episode “Cardior 🇩🇪 | Being the Founder of a Rare €1B Exit” is an hour-long deep dive into the details of the acquisition, the therapeutic potential and clinical development of our lead compound #CD132L as a novel treatment for cardiovascular disease, the story of how Cardior was founded and the inspiring career of Dr. Ulbrich as a biotech entrepreneur. Listen to the full episode here: https://lnkd.in/eB5vp34D

We are happy to announce that the transaction on the acquisition of Cardior Pharmaceuticals by Novo Nordisk is officially completed and as of May 2, 2024 Cardior has become a fully owned subsidiary of Novo Nordisk A/S. We at Cardior see it as a very important step towards accelerating the late-stage clinical development of our lead compound. We are looking forward to combining forces with Novo Nordisk and working together towards our common goal - developing life-saving treatment for heart patients.  The transition process is now underway, and we’ve already had the pleasure of welcoming Novo Nordisk Team at Cardior premises in Hannover and spending two exciting days together. On the photo: The first visit of Novo Nordisk Team to Cardior’s premises in Hannover.